A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells

被引:93
作者
Hu, Wenwei
Feng, Zhaohui
Ma, Lan
Wagner, John
Rice, J. Jeremy
Stolovitzky, Gustavo
Levine, Arnold J.
机构
[1] Univ Med & Dent New Jersey, Canc Inst New Jersey, Newark, NJ 07103 USA
[2] IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA
[3] Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA
关键词
D O I
10.1158/0008-5472.CAN-06-2656
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oscillations of both p53 and MDM2 proteins have been observed in cells after exposure to stress. A mathematical model describing these oscillations predicted that oscillations occur only at selected levels of p53 and MDM2 proteins. This model prediction suggests that oscillations will disappear in cells containing high levels of MDM2 as observed with a single nucleotide polymorphism in the MDM2 gene (SNP309). The effect of SNP309 upon the p53-MDM2 oscillation was examined in various human cell lines and the oscillations were observed in the cells with at least one wild-type allele for SNP309 (T/T or T/G) but not in cells homozygous for SNP309 (G/G). Furthermore, estrogen preferentially stimulated the transcription of MDM2 from SNP309 G allele and increased the levels of MDM2 protein in estrogen-responsive cells homozygous for SNP309 (G/G). These results suggest the possibility that SNP309 G allele may contribute to gender-specific tumorigenesis through further elevating the MDM2 levels and disrupting the p53-MDM2 oscillation. Furthermore, using the H1299-HW24 cells expressing wild-type p53 under a tetracycline-regulated promoter, the p53-MDM2 oscillation was observed only when p53 levels were in a specific range, and DNA damage was found to be necessary for triggering the p53-MDM2 oscillation. This study shows that higher levels of MDM2 in cells homozygous for SNP309 (G/G) do not permit coordinated p53-MDM2 oscillation after stress, which might contribute to decreased efficiency of the p53 pathway and correlates with a clinical phenotype (i.e., the development of cancers at earlier age of onset in female).
引用
收藏
页码:2757 / 2765
页数:9
相关论文
共 39 条
[1]   The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck [J].
Alhopuro, P ;
Ylisaukko-oja, SK ;
Koskinen, WJ ;
Bono, P ;
Arola, J ;
Järvinen, HJ ;
Mecklin, JP ;
Atula, T ;
Kontio, R ;
Mäkitie, AA ;
Suominen, S ;
Leivo, I ;
Vahteristo, P ;
Aaltonen, LM ;
Aaltonen, LA .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (09) :694-698
[2]   Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study [J].
Bar-Or, RL ;
Maya, R ;
Segel, LA ;
Alon, U ;
Levine, AJ ;
Oren, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (21) :11250-11255
[3]  
Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO
[4]  
2-Y
[5]   MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner [J].
Bond, Gareth L. ;
Hirshfield, Kim M. ;
Kirchhoff, Tomas ;
Alexe, Gabriella ;
Bond, Elisabeth E. ;
Robins, Harlan ;
Bartel, Frank ;
Taubert, Helge ;
Wuerl, Peter ;
Hait, William ;
Toppmeyer, Deborah ;
Offit, Kenneth ;
Levine, Arnold J. .
CANCER RESEARCH, 2006, 66 (10) :5104-5110
[6]   MDM2 is a central node in the p53 pathway: 12 years and counting [J].
Bond, GL ;
Hu, WW ;
Levine, AJ .
CURRENT CANCER DRUG TARGETS, 2005, 5 (01) :3-8
[7]   A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].
Bond, GL ;
Hu, WW ;
Bond, EE ;
Robins, H ;
Lutzker, SG ;
Arva, NC ;
Bargonetti, J ;
Bartel, F ;
Taubert, H ;
Wuerl, P ;
Onel, K ;
Yip, L ;
Hwang, SJ ;
Strong, LC ;
Lozano, G ;
Levine, AJ .
CELL, 2004, 119 (05) :591-602
[8]   Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome [J].
Bougeard, G. ;
Baert-Desurmont, S. ;
Tournier, I. ;
Vasseur, S. ;
Martin, C. ;
Brugieres, L. ;
Chompret, A. ;
Bressac-de Paillerets, B. ;
Stoppa-Lyonnet, D. ;
Bonaiti-Pellie, C. ;
Frebourg, T. .
JOURNAL OF MEDICAL GENETICS, 2006, 43 (06) :531-533
[9]   Abnormal expression of MDM-2 in breast carcinomas [J].
BuesoRamos, CE ;
Manshouri, T ;
Haidar, MA ;
Yang, Y ;
McCown, P ;
Ordonez, N ;
Glassman, A ;
Sneige, N ;
Albitar, M .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 37 (02) :179-188
[10]   p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells [J].
Chen, XB ;
Ko, LJ ;
Jayaraman, L ;
Prives, C .
GENES & DEVELOPMENT, 1996, 10 (19) :2438-2451